AllCells

Executive Summary

AllCells, operating as a brand under Discovery Life Sciences, is a premier provider of high-quality human primary cells and whole tissue products for the life science research and cell & gene therapy (CGT) development markets. Founded in 1998 and headquartered in Alameda, California, the company specializes in donor management and custom prospective collections of hematological tissues, offering a range of products including mobilized leukopaks, bone marrow, cord blood, and peripheral blood mononuclear cells (PBMCs) in both fresh and cryopreserved formats. By serving the CGT development continuum from research use only (RUO) to Good Manufacturing Practice (GMP) grade, AllCells enables researchers and biopharmaceutical companies to accelerate drug discovery, preclinical studies, and clinical manufacturing. Its integration into Discovery Life Sciences expands its global reach and capabilities, providing end-to-end biospecimen solutions. As the cell and gene therapy field continues to grow rapidly, AllCells is well-positioned to benefit from increasing demand for high-quality, well-characterized primary cells and tissues. The company's focus on GMP-grade products is particularly timely, as more therapies advance toward commercialization. While AllCells does not disclose financials, its role as a critical supplier in the CGT ecosystem suggests steady revenue growth. Key risks include competition from other biospecimen providers and potential supply chain disruptions. Overall, AllCells represents a stable, essential service provider in a high-growth sector.

Upcoming Catalysts (preview)

• Q3 2026Expansion of GMP-grade product portfolio to support late-stage clinical trials80% success
• TBDStrategic partnership with a major cell therapy developer for exclusive biospecimen supply60% success
• Q1 2027Launch of a novel donor screening program for rare cell types70% success